Benchmark Maintains Buy on Agilon Health, Lowers Price Target to $95

Benzinga Newsdesk www.benzinga.com Neutral 57.1%

Neg 0% Neu 57.1% Pos 0%

Benchmark analyst Bill Sutherland maintains Agilon Health (NYSE:AGL) with a Buy and lowers the price target from $13 to $95.